PPARG and persistent fetal circulation syndrome: Although all these experimental studies demonstrate a potential role for PPAR-γ agonists, such as rosiglitazone and 15D-prostaglandin-J2, in the treatment of PPHN, no studies involving human infants have yet been conducted.